Please assess the completion status of the following clinical trial:

Trial Title: Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. more than 20 years old~2. HCCs diagnosed by AASLD image criteria or pathology~3. Intermediate-stage HCCs that TACE is indicated~4. chronic HBV carrier with detectable HBV DNA in blood~5. ECOG performance status (PST) 0-2~6. Child-Pugh score ≦7~7. serum bilirubin \< 2 mg/dL~8. prothrombin time prolongation \< 3 seconds~9. willingness to adhere to treatment and follow-up plans -~Exclusion Criteria:~1. any vascular invasion by tumors~2. extra-hepatic metastasis~3. concurrent any other malignancy~4. concomitant immunosuppressive therapy~5. HCC recurrence within 2 years of previous curative treatment~6. antiviral therapy for chronic hepatitis B within 6 months before HCC diagnosis~7. concomitant other therapies for HCC except TACE~8. liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy~9. contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage~10. contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc.~11. chronic renal failure with eGFR \< 60~12. concurrent any other chronic viral hepatitis with HCV, HDV, or HIV) -

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tenofovir treatment (Type: ACTIVE_COMPARATOR): Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
- Placebo (Type: PLACEBO_COMPARATOR): Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).